PHARCO Pharmaceuticals, Inc. announced today that the World Health Organization (WHO) has awarded prequalification for SOFOSBUVIR 400 mg Tablets manufactured at its European Egyptian Pharmaceutical Industries (EEPI) Factory for the treatment of Hepatitis C Virus (HCV).
More than 800,000 Egyptians have been cured from hepatitis C since January 2016 and 2020 will not see this country with one single Virus C patient